FAQs

INVESTORS & MEDIA

INVESTORS
& MEDIA

 

Leonard S. Schleifer, M.D., Ph.D. founded Regeneron in 1988, along with Alfred G. Gilman M.D., Ph.D. and Eric M. Shooter, Ph.D. Dr. Schleifer is President and CEO; Dr. Gilman, a Nobel Laureate and Provost Dean of The University of Texas Southwestern Medical School, is a Director; Dr. Shooter, a Professor at Stanford University School of Medicine since 1968 and now a Professor Emeritus, is also a Director.

The Company was incorporated in 1988 in the State of New York.

We started trading publicly in April 1991.

Our corporate headquarters and research laboratories are located in Tarrytown, NY, our large-scale manufacturing facilities are located in Rensselaer, NY and Limerick, Ireland, our satellite offices are located in Sleepy Hollow, NY and Basking Ridge, NJ, and our European business offices are located in Dublin, Ireland and London, United Kingdom.

As of October 2017, we have nearly 6,000 regular employees. 

Shares of our common stock are listed on The NASDAQ Global Select Market under the symbol REGN.

The most up-to-date number of shares outstanding can be found on the Financial Information page in the Investor Relations section of our Web site.

You can purchase stock in our company through a registered brokerage or stock purchase service provider of your choice. You cannot buy Regeneron stock directly from the company.

You will need to contact the broker from whom you purchased your shares.

American Stock Transfer & Trust
59 Maiden Lane
Plaza Level
New York, NY 10038
(800) 937-5449

No, we have never paid a cash dividend nor do we expect to pay any dividends in the foreseeable future.

We typically report quarterly financial results approximately 30 days after the final day of the quarter. We do not host quarterly conference calls to discuss our financial results. You can access our earnings press releases in the Investor Relations section of our Web site.

Our Annual Meeting of Stockholders is held each June in Tarrytown, New York.

Proxy statements are available through the Investor Relations section of our Web site under the heading "SEC Filings."

Proxy statements are available through the Investor Relations section of our Web site under the heading "SEC Filings."

PricewaterhouseCoopers LLC

If you can't find the information you're looking for on our Web site, please feel free to contact Investor Relations at (914) 847-7741. 

Please visit the Financial Information pages of the Investor Relations section of our Web site or refer to the most recent 10-Q or 10-K report under the heading "SEC Filings."

Please visit the Investor Relations section of our Web site and choose the "Email Alerts" tab to be added to the Regeneron distribution list.

Please submit your question using the form below.

* Indicates required field